Anti-HER2 monoclonal antibodies may be a straightforward substitute for combination with antiangiogenic therapeutics like mCHT as pre-clinical research suggests they can reduce angiogenesis and tumor growth by controlling pro- and antiangiogenic factors [130,131]. This evidence concerns the gene ERBB2 and neoplasm.